We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · May 03, 2022

Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With ER+ Breast Cancer

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor-Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial
J. Clin. Oncol 2022 Apr 20;[EPub Ahead of Print], SB Vliek, I Noordhoek, E Meershoek-Klein Kranenbarg, AGJ van Rossum, VO Dezentje, A Jager, JWE Hokken, H Putter, AWG van der Velden, MP Hendriks, SD Bakker, YEA van Riet, VCG Tjan-Heijnen, JEA Portielje, JR Kroep, JWR Nortier, CJH van de Velde, SC Linn

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading